Rational Design of Inhibitors of HIV-1 TAR RNA through the Stabilisation of Electrostatic "Hot Spots"

Journal of Molecular Biology

Volumn 336, Issue 2, 2004, Pages 343-356

  Davis, Ben ^a   Afshar, Mohammad ^a,c   Varani, Gabriele ^b,e   Murchie, Alastair I H ^a   Karn, Jonathan ^b,d   Lentzen, Georg ^a,f   Drysdale, Martin ^a   Bower, Justin ^a   Potter, Andrew J ^a   Starkey, Ian D ^a   Swarbrick, Terry ^a   Aboul Ela, Fareed ^a  

^a RiboTargets Ltd   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c Ariana Pharma   (France)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f BITOP AG   (Germany)

Author keywords

Drug design; Hot spots; NMR; Structure activity relationships (SAR); TAR RNA

Indexed keywords

GUANIDINE DERIVATIVE; LIGAND; PHOSPHATE; RNA; TRANSACTIVATOR PROTEIN; VIRUS RNA;

ARTICLE; CALCULATION; CONFORMATION; DNA RESPONSIVE ELEMENT; DRUG DESIGN; ELECTRICITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MODEL; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN RNA BINDING; PROTEIN STRUCTURE; RNA CONFORMATION; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION; VIRUS INHIBITION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 9144274314     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2003.12.046     Document Type: Article

References (64)

1. Ramakrishnan V. Ribosome structure and the mechanism of translation. Cell. 108:2002;557-572.
2. Gallego J., Varani G., Targeting R.N.A. with small-molecule drugs: therapeutic promise and chemical challenges. Acc. Chem. Res. 34:2001;836-843.
3. Drysdale M.J., Lentzen G., Matassova N., Murchie A.I.H., Aboul-ela F., Afshar M. RNA as a drug target. Prog. Med. Chem. 39:2002;73-119.
4. Foreyen M., Herdewijn P. RNA as a target for drug design, the example of Tat-TAR interaction. Curr. Top. Med. Chem. 2:2002;1123-1145.
5. Delling U., Reid L.S., Barnett R.W., Ma M.Y.-X., Climie S., Sumner-Smith M., Sonenberg N. Conserved nucleotides in the TAR RNA stem of human immunodeficiency virus type 1 are critical for Tat binding and trans activation: model for TAR RNA tertiary structure. J. Virol. 66:1992;3018-3025.
6. Dingwall C., Ernberg I., Gait M.J., Green S.M., Heaphy S., Karn J., et al. Human immunodeficiency virus 1 tat protein binds trans-activation- responsive region (TAR) RNA in vitro. Proc. Natl Acad. Sci. USA. 86:1989;6925-6929.
7. Churcher M.J., Lamont C., Hamy F., Dingwall C., Green S.M., Lowe A.D., et al. High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region. J. Mol. Biol. 230:1993;90-110.
8. Colvin R.A., Garcia-Blanco M.A. Unusual structure of the human immunodeficiency virus type 1 trans-activation response element. J. Virol. 66:1992;930-935.
9. Weeks K.M., Ampe C., Schultz S.C., Steitz T.A., Crothers D.M. Fragments of the HIV-I Tat protein specifically bind TAR RNA. Science. 249:1990;1281-1285.
10. Weeks K.M., Crothers D.M. RNA recognition by Tat-derived peptides: interaction in the major groove? Cell. 66:1991;577-588.
11. Hamy F., Asseline V., Grasby J., Iwai S., Pritchard C., Slim G., et al. Hydrogen bonding contacts in the major groove are required for human immunodeficiency virus type-1 Tat protein recognition of TAR RNA. J. Mol. Biol. 230:1993;111-123.
12. Pritchard C.E., Grasby J.A., Hamy F., Zacharek A.M., Singh M., Karn J., Gait M.J. Methylphosphonate mapping of phosphate contacts critical for RNA recognition by the human immunodeficiency virus tat and rev proteins. Nucl. Acids Res. 22:1994;2592-2600.
13. Arzumanov A., Walsh A.P., Rajwanshi V.K., Kumar R., Wengel J., Gait M.J. Inhibition of HIV-1 tat-dependent trans activation by steric block chimeric 2′-o-methyl/LNA oligoribonucleotides. Biochemistry. 40:2001;14645-14654.
14. Karn J. Tackling Tat. J. Mol. Biol. 293:1999;235-254.
15. Mischiati C., Jeang K.-T., Feriotto G., Breda L., Borgatti M., Bianchi N., Gambari R. Aromatic polyamidines inhibiting the tat-induced HIV-1 transcription recognize structured TAR-RNA. Antisense Nucl. Acid Drug Dev. 11:2001;209-217.
16. Hamma T., Saleh A., Huq I., Rana T.M., Miller P.S. Inhibition of HIV Tat-TAR interaction by an antisense oligo-2′-O-methylribonucleoside methylphosphonate. Bioorg. Med. Chem. Letters. 13:2003;1845-1848.
17. Kaushik N., Basu A., Palumbo P., Myers R.L., Pandey V.N. Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J. Virol. 76:2002;3881-3891.
18. Holmes S.C., Arzumanov A.A., Gait M.J. Steric inhibition of human immunodeficiency virus type-1 Tat-dependent trans-activation in vitro and in cells by oligonucleotides containing 2′-O-methyl G-clamp ribonucleoside analogues. Nucl. Acids Res. 31:2003;2759-2768.
19. Lind K.E., Du Z., Fujinaga K., Peterlin B.M., James T.L. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target RNA. Chem. Biol. 9:2002;185-193.
20. Swayze E.E., Jefferson E.A., Sannes-Lowery K.A., Blyn L.B., Risen L.M., Arakawa S., et al. SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. J. Med. Chem. 45:2002;3816-3819.
21. Yu L., Oost T.K., Schkeryantz J.M., Yang J., Janowick D., Fesik S.W. Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA. J. Am. Chem. Soc. 125:2003;4444-4450.
22. Du Z., Lind K.E., James T.L. Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening. Chem. Biol. 9:2002;707-712.
23. Russell R.J., Murray J.B., Lentzen G., Haddad J., Mobashery S. The complex of a designer antibiotic with a model aminoacyl site of the 30 S ribosomal subunit revealed by X-ray crystallography. J. Am. Chem. Soc. 125:2003;3410-3411.
24. Puglisi J.D., Tan R., Calnan B.J., Frankel A.D., Williamson J.R. Conformation of the TAR RNA-arginine complex by NMR spectroscopy. Science. 257:1992;76-80.
25. Aboul-ela F., Karn J., Varani G. The structure of the human immunodeficiency virus type-1 TAR reveals principles of RNA recognition by Tat protein. J. Mol. Biol. 253:1995;313-332.
26. Aboul-ela F., Karn J., Varani G. Structure of HIV-1 TAR RNA in the absence of ligands reveals a novel conformation of the trinucleotide bulge. Nucl. Acids Res. 24:1996;3974-3981.
27. Brodsky A.S., Williamson J.R. Solution structure of the HIV-2 TAR-argininamide complex. J. Mol. Biol. 267:1997;624-639.
28. Brodsky A.S., Erlacher H., Williamson J.R. NMR evidence for a base triple in the HIV-2 TAR C-G*C mutant-argininamide complex. Nucl. Acids Res. 26:1998;1991-1995.
29. Ippolito J., Steitz T.A. A 1.3 angstrom resolution crystal structure of the HIV-1 trans-activation response region RNA stem reveals a metal ion-dependent bulge conformation. Proc. Natl Acad. Sci. USA. 95:1998;9819-9824.
30. Long K.S., Crothers D.M. Characterization of the solution conformations of unbound and Tat peptide-bound forms of HIV-1 TAR RNA. Biochemistry. 38:1999;10059-10069.
31. Al-Hashimi H.M., Gosser Y., Gorin A., Hu W., Majumdar A., Patel D.J. Concerted motions in HIV-1 TAR RNA may allow access to bound state conformations: RNA dynamics from NMR residual dipolar couplings. J. Mol. Biol. 315:2002;95-102.
32. Murchie ., Davis A.I.H., Isel B., Afshar C., Drysdale M., Bower M.J., et al. Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA. J. Mol. Biol. 2004;. In the press.
33. Puglisi J.D.C.L., Frankel A.D., Williamson J.R. Role of RNA structure in arginine recognition of TAR RNA. Proc. Natl Acad. Sci. USA. 90:1993;3680-3684.
34. Hermann T., Westhof E. Docking of cationic antibiotics to negatively charged pockets in RNA folds. J. Med. Chem. 42:1999;1250-1261.
35. Nifosi R., Reyes C.M., Kollman P.A. Molecular dynamics studies of the HIV-1 TAR and its complex with argininamide. Nucl. Acids Res. 28:2000;4944-4955.
36. Tao J., Frankel A.D. Electrostatic interactions modulate the RNA-binding and transactivation specificities of the human immunodeficiency virus and simian immunodeficiency virus Tat proteins. Proc. Natl Acad. Sci. USA. 90:1993;1571-1575.
37. Aboul-ela F., Varani G. Recognition of HIV-1 TAR RNA by Tat protein and Tat-derived peptides. J. Mol. Struct. (Theochem.). 423:1998;29-39.
38. Chin K., Sharp K.A., Honig B., Pyle A.M. Calculating the electrostatic properties of RNA provides new insights into molecular interactions and function. Nature Struct. Biol. 11:1999;1055-1061.
39. DeLano W.L. Unraveling hot spots in binding interfaces: progress and challenges. Curr. Opin. Struct. Biol. 12:2002;14-20.
40. Hamy F., Felder E.R., Heizmann G., Lazdins J., Aboul-ela F., Varani G., et al. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl Acad. Sci. USA. 94:1997;3548-3553.
41. Varani G., Aboul-ela F., Allain F.H.-T. NMR investigation of RNA structure. Prog. Nucl. Magn. Reson. Spectrosc. 29:1996;51-127.
42. Dougherty D.A. Cation-π interactions in chemistry and biology: a new view of benzene, phe, tyr, and trp. Science. 271:1996;163-168.
43. Long K.S., Crothers D.M. Interaction of human immunodeficiency virus type 1 Tat-derived peptides with TAR RNA. Biochemistry. 34:1995;8885-8895.
44. Gait M.J., Karn J. RNA recognition by the human immunodeficiency virus Tat and Rev proteins. Trends Biochem. Sci. 18:1993;255-259.
45. Olejniczak M., Gdaniec Z., Fischer A., Grabarkiewicz T., Bielecki L., Adamiak R.W. The bulge region of HIV-1 TAR RNA binds metal ions in solution. Nucl. Acids Res. 30:2002;4241-4249.
46. Battiste J.L., Mao H., Rao N.S., Tan R., Muhandiram D.R., Kay L.E., et al. α-helix-RNA major groove recognition in an HIV-1 Rev peptide-RRE RNA complex. Science. 273:1996;1547-1551.
47. Legault P., Li J., Mogridge J., Kay L.E., Greenblatt J. NMR structure of the bacteriophage λ N peptide/boxB RNA complex: recognition of a GNRA fold by an arginine-rich motif. Cell. 93:1998;289-299.
48. Peterson R.D., Feigon J. Structural change in Rev responsive element RNA of HIV-1 on binding Rev peptide. J. Mol. Biol. 264:1996;863-877.
49. Delling U., Roy S., Sumner-Smith M., Barnett R., Reid L., Rosen C.A., Sonenberg N. The number of positively charged amino acids in the basic domain of Tat is critical for trans-activation and complex formation with TAR RNA. Proc. Natl Acad. Sci. USA. 88:1991;6234-6238.
50. Calnan B.J., Biancalana S., Hudson D., Frankel A.D. Analysis of arginine-rich peptides from the HIV Tat protein reveals unusual features of RNA-protein recognition. Genes Dev. 5:1991;201-210.
51. Tan R., Frankel A.D. Circular dichroism studies suggest that TAR RNA changes conformation upon binding of arginine or guanidine. Biochemistry. 31:1992;10288-10294.
52. Tao J., Chen L., Frankel A.D. Dissection of the proposed base triple in human immunodeficiency virus TAR RNA indicates the importance of the hoogsteen interaction. Biochemistry. 36:1997;3491-3495.
53. Puglisi J.D., Chen L., Blanchard S., Frankel A.D. Solution structure of a bovine immunodeficiency virus Tat-TAR peptide-RNA complex. Science. 270:1995;1200-1203.
54. Ye X., Kumar R.A., Patel D.J. Molecular recognition in the bovine immunodeficiency virus Tat peptide-TAR RNA complex. Curr. Biol. 2:1995;827-840.
55. Wang Z., Shah K., Rana T. Probing tat peptide-TAR RNA interactions by psoralen photo-cross-linking. Biochemistry. 40:2001;6458-6464.
56. Faber C.S.H., Schweimer K., Rosch P. Structural rearrangements of HIV-tat-responsive RNA upon binding of neomycin B. J. Biol. Chem. 275:2000;20660-20666.
57. Milligan J.F., Uhlenbeck O.C. Synthesis of small RNAs using T7 RNA polymerase. Methods Enzymol. 180:1988;51-62.
58. Puglisi J.D., Tinoco I. Absorbance melting curves of RNA. Methods Enzymol. 180:1989;304-325.
59. Drysdale, M. J., Starkey, I. D., Swarbrick, T. M., Potter, A. J. & Bower, J. F. (2002) Preparation of arallkylguanidines related compounds for treatment of viral infection, WO 2001-GB2816, WO 2002000614 2002, 57.
60. Delaglio F., Grzesiak S., Vuister G., Zhu G., Pfeifer J., Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR. 6:1995;277-293.
61. Hennig M., Williamson J.R. Detection of N-H bond N hydrogen bonding in RNA via scalar couplings in the absence of observable imino proton resonances. Nucl. Acids Res. 28:2000;1585-1593.
62. Diamond R. On the multiple simultaneous superposition of molecular structures by rigid body transformations. Protein Sci. 1:1992;1279-1287.
63. Diamond R. Coordinate-based cluster analysis. Acta Crystallog. sect. D. D51:1995;127-135.
64. Karn J., Gait M.J., Churcher M.J., Mann D.A., Mikaelian I.P.C. Control of human immunodeficiency virus gene expression by the RNA binding proteins Tat and Rev. Nagai K., Mattai I.W. RNA-Protein Interactions. 1995;192-220 IRL Press, Oxford.